{"url_path":"/sec/nvcr/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000056-index.html","accession_number":"0001645113-26-000056","cik":"0001645113","ticker":"NVCR","issuer_name":"NovoCure Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000056-index.html","primary_entity_key":"0001645113","primary_entity_name":"NovoCure Ltd"},"word_count":146,"has_tables":true,"body_markdown":"Item 7.01     Regulation FD Disclosure.\n\nOn June 30, 2026, the Company issued a press release announcing that that that Optune Pax® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with locally-advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. Because the use of gemcitabine and nab-paclitaxel may vary by market, the approved CE Mark intended purpose for Optune Pax includes a reference to guideline recommendations to account for these local differences.\n\nThe information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}